case_images: PMC10764081_01
case_images: Clinical images of laBSCs involving the ocular area treated with sonidegib: an ulcerated plaque with superficial crusts, extending from the medial to lateral canthus (a), showing a clinical response after 4 months of therapy (b), maintained after 12 months of therapy (c); disease recurrence manifesting only with conjunctival hyperemia (d), with no clinical improvement after 6 months of therapy (e), developing a firm nodular lesion on the infraorbital region after 12 months of therapy (f); tumor enlarging on the lower eyelid margin and lateral canthus (g) that exhibits significant improvement after 12 months of therapy (h) and after 18 months of therapy (i).
case_images: cde-2024-0016-0001-535506_F01.jpg
case_images: PMC10764081_03_cde-2024-0016-0001-535506_F01.jpg
case_images: F1
case_images: A 63-year-old male patient was referred to our department by the ophthalmologist for a BSC infiltrating the external canthus and the inferior tarsal conjunctiva of the left eye (Fig. 1g). After 12 months of therapy, the disease was stable with persistence of the drug-related adverse events (Fig. 1h). At 18 months of therapy, there was no disease recurrence (Fig. 1i), and an incisional biopsy performed to confirm CR resulted in healthy scar tissue.
case_images: PMC10764081_02
case_images: Clinical images of laBSCs involving the ocular area treated with sonidegib: an ulcerated plaque with superficial crusts, extending from the medial to lateral canthus (a), showing a clinical response after 4 months of therapy (b), maintained after 12 months of therapy (c); disease recurrence manifesting only with conjunctival hyperemia (d), with no clinical improvement after 6 months of therapy (e), developing a firm nodular lesion on the infraorbital region after 12 months of therapy (f); tumor enlarging on the lower eyelid margin and lateral canthus (g) that exhibits significant improvement after 12 months of therapy (h) and after 18 months of therapy (i).
case_images: cde-2024-0016-0001-535506_F01.jpg
case_images: PMC10764081_03_cde-2024-0016-0001-535506_F01.jpg
case_images: F1
case_images: A 63-year-old male patient was referred to our department by the ophthalmologist for a BSC infiltrating the external canthus and the inferior tarsal conjunctiva of the left eye (Fig. 1g). After 12 months of therapy, the disease was stable with persistence of the drug-related adverse events (Fig. 1h). At 18 months of therapy, there was no disease recurrence (Fig. 1i), and an incisional biopsy performed to confirm CR resulted in healthy scar tissue.
case_images: PMC10764081_03
case_images: Clinical images of laBSCs involving the ocular area treated with sonidegib: an ulcerated plaque with superficial crusts, extending from the medial to lateral canthus (a), showing a clinical response after 4 months of therapy (b), maintained after 12 months of therapy (c); disease recurrence manifesting only with conjunctival hyperemia (d), with no clinical improvement after 6 months of therapy (e), developing a firm nodular lesion on the infraorbital region after 12 months of therapy (f); tumor enlarging on the lower eyelid margin and lateral canthus (g) that exhibits significant improvement after 12 months of therapy (h) and after 18 months of therapy (i).
case_images: cde-2024-0016-0001-535506_F01.jpg
case_images: PMC10764081_03_cde-2024-0016-0001-535506_F01.jpg
case_images: F1
case_images: A 63-year-old male patient was referred to our department by the ophthalmologist for a BSC infiltrating the external canthus and the inferior tarsal conjunctiva of the left eye (Fig. 1g). After 12 months of therapy, the disease was stable with persistence of the drug-related adverse events (Fig. 1h). At 18 months of therapy, there was no disease recurrence (Fig. 1i), and an incisional biopsy performed to confirm CR resulted in healthy scar tissue.
case_images: PMC10764081_04
case_images: Clinical images of a laBSCs involving the ocular area and the retro-auricolar area treated with sonidegib: tumor extending on the medial canthus and lower and upper eyelids (a), not showing clinical improvement after 6 months of therapy (b); an ulcerated crusted plaque with irregular margin invading the posterior area of the auricle (c), with clinical response after 3 months of therapy (d).
case_images: cde-2024-0016-0001-535506_F02.jpg
case_images: PMC10764081_05_cde-2024-0016-0001-535506_F02.jpg
case_images: F2
case_images: One of these lesions was an ulcerated, bleeding BSC (2.4 x 1.7 cm) located on the right retro-auricular area (Fig. 2c). Given the presence of multiple skin lesions and the complexity of surgical reconstruction, sonidegib 200 mg per day was started, achieving a PR after 3 months, with a reduction of approximately 50% of the target lesion (Fig. 2d) and other BCCs.
case_images: PMC10764081_05
case_images: Clinical images of a laBSCs involving the ocular area and the retro-auricolar area treated with sonidegib: tumor extending on the medial canthus and lower and upper eyelids (a), not showing clinical improvement after 6 months of therapy (b); an ulcerated crusted plaque with irregular margin invading the posterior area of the auricle (c), with clinical response after 3 months of therapy (d).
case_images: cde-2024-0016-0001-535506_F02.jpg
case_images: PMC10764081_05_cde-2024-0016-0001-535506_F02.jpg
case_images: F2
case_images: One of these lesions was an ulcerated, bleeding BSC (2.4 x 1.7 cm) located on the right retro-auricular area (Fig. 2c). Given the presence of multiple skin lesions and the complexity of surgical reconstruction, sonidegib 200 mg per day was started, achieving a PR after 3 months, with a reduction of approximately 50% of the target lesion (Fig. 2d) and other BCCs.